creating and capturing value with biomarkers
DESCRIPTION
Talk presented at ACI Biomarker Utilisation & Commercialisation conference 2014. Talk provides an overview of the key considerations in developing and launching biomarkers and the associated platforms.TRANSCRIPT
5 September 2014 S4998-P-634 v1.0
Capturing and creating value with biomarkers
Dean Griffiths PhD
ACI Biomarker Utilisation & Commercialisation conference
5 September 2014 S4998-P-634 v1.02
Introduction to Cambridge Consultants - A world leader in technology and product innovation
Established out of The University of Cambridge in 1960 Approximately 430 scientists and engineers For clients globally, we
– design and develop breakthrough products
– create and license intellectual property
– provide business consulting in technology critical issues
5 September 2014 S4998-P-634 v1.03
Summary
Understand user needs
Solutions require biomarker and platform
Enable solutions which scale
5 September 2014 S4998-P-634 v1.04Commercially Confidential
Agenda
6 Summary
5 Where next for biomarkers
4 Scaling user adoption
3 Enabling user adoption
2 Creating value by aligning to user needs
1 How do users benefit from biomarkers?
5 September 2014 S4998-P-634 v1.05
Researchers, clinicians and consumers
5 September 2014 S4998-P-634 v1.06
Data, therapies and advice
5 September 2014 S4998-P-634 v1.07Commercially Confidential
Agenda
6 Summary
5 Where next for biomarkers
4 Scaling user adoption
3 Enabling user adoption
2 Creating value by aligning to user needs
1 How do users benefit from biomarkers?
5 September 2014 S4998-P-634 v1.08
Creating value by aligning to user needs
5 September 2014 S4998-P-634 v1.09
Creating value by aligning to user needs
Biomarkers are not new;
"Shushrut statue" by Alokprasad at en.wikipedia
5 September 2014 S4998-P-634 v1.010
Creating value by aligning to user needs
The need for biomarkers is growing as more targeted cancer therapies increase their market share
Reproduced from (Aitken, 2014)
5 September 2014 S4998-P-634 v1.011
16%
48%
37% Drugs with FDA-approved CDx
Drugs with FDA-approved biomarkers
Other Drugs
Creating value by aligning to user needs
Although many targeted cancer therapies still lack biomarkers
2008 2013
13%
57%
30%
Cambridge Consultants analysis 2014
5 September 2014 S4998-P-634 v1.012
Creating value by aligning to user needs
5 September 2014 S4998-P-634 v1.013
Creating value by aligning to user needs
5 September 2014 S4998-P-634 v1.014
Creating value by aligning to user needs
Where are the tumour cells?
Folate receptor-α targeted fluorescent agent
Van Dam et al Nature Medicine 17, 1315–1319 (2011)
5 September 2014 S4998-P-634 v1.015
Creating value by aligning to user needs
Where are the tumour cells?
Folate receptor-α targeted fluorescent agent
Van Dam et al Nature Medicine 17, 1315–1319 (2011)
5 September 2014 S4998-P-634 v1.016
Creating value by aligning to user needs
Biomarkers used in vivo can detect more tumours
Van Dam et al Nature Medicine 17, 1315–1319 (2011)
5 September 2014 S4998-P-634 v1.017
Creating value by aligning to user needs
Multiple companies are already active in this space
5 September 2014 S4998-P-634 v1.018Commercially Confidential
Agenda
6 Summary
5 Where next for biomarkers
4 Scaling user adoption
3 Enabling user adoption
2 Creating value by aligning to user needs
1 How do users benefit from biomarkers?
5 September 2014 S4998-P-634 v1.019
Enabling user adoption
5 September 2014 S4998-P-634 v1.020
Enabling user adoption
Demonstrate utility
Image: Illumina
5 September 2014 S4998-P-634 v1.021
Enabling user adoption
Enable users to be able to access the platform and biomarkers
The Economist
5 September 2014 S4998-P-634 v1.022
Enabling user adoption
Ensure that the platform and biomarker are easy to use and interpret
Image: Illumina
5 September 2014 S4998-P-634 v1.023
Enabling user adoption
Information not just data
Image: Illumina
5 September 2014 S4998-P-634 v1.024Commercially Confidential
Agenda
6 Summary
5 Where next for biomarkers
4 Scaling user adoption
3 Enabling user adoption
2 Creating value by aligning to user needs
1 How do users benefit from biomarkers?
5 September 2014 S4998-P-634 v1.025
Scaling user adoption
Scale is king
5 September 2014 S4998-P-634 v1.026
Scaling user adoption
5 September 2014 S4998-P-634 v1.027
Scaling user adoption
Decrease barriers to entry
Image: Abcam
5 September 2014 S4998-P-634 v1.028
Scaling user adoption
Increase data confidence
Image: Abcam
5 September 2014 S4998-P-634 v1.029
Scaling user adoption
Generate publicity and goodwill
Image: Abcam
5 September 2014 S4998-P-634 v1.030Commercially Confidential
Agenda
6 Summary
5 Where next for biomarkers
4 Scaling user adoption
3 Enabling user adoption
2 Creating value by aligning to user needs
1 How do users benefit from biomarkers?
5 September 2014 S4998-P-634 v1.031
Where next for biomarkers
New analytes
Image: Senior Airman Sandra Welch
5 September 2014 S4998-P-634 v1.032
Where next for biomarkers
Non-invasive
5 September 2014 S4998-P-634 v1.033
Where next for biomarkers
Predictive
Image: Sgt Eric T. Sheler - USAF
5 September 2014 S4998-P-634 v1.034Commercially Confidential
Agenda
6 Summary
5 Where next for biomarkers
4 Scaling user adoption
3 Enabling user adoption
2 Creating value by aligning to user needs
1 How do users benefit from biomarkers?
5 September 2014 S4998-P-634 v1.035
Summary
Understand user needs
Solutions require biomarker and platform
Enable solutions which scale
5 September 2014 S4998-P-634 v1.0
Cambridge UK
Registered No. 1036296 England
Cambridge Consultants is part of the Altran group, a global leader in Innovation. www.Altran.com
www.CambridgeConsultants.comThe contents of this presentation are commercially confidential and the proprietary information of Cambridge Consultants © 2014 Cambridge Consultants Ltd. All rights reserved.
Boston USA Singapore
+44 1223 392139